Pharmaceutical company Biocon has reported better than expected topline as well as bottomline numbers in its fourth quarter of FY12. Its net profit fell 3% to Rs 98 crore in the January-March quarter of 2012 from Rs 101 crore in a year ago period.
Pfizer - Biocon alliance has called off due to individual priorities and in Shares of Biocon fell more than 8% on Tuesday morning after US pharma major Pfizer scrapped a deal to sell insulin products made by the Bangalore-based biotechnology company.
Biocon, India's top-listed biotechnology company, expects to generate larger licensing income from pharmaceuticals business, its Chairman and Managing Director said on Wednesday.
In the wake of the depreciation of the Rupee against the US Dollar, India needs to implement measures in a considered and thoughtful way, Chairperson and Managing Director of Biocon Limited, Kiran Mazumdar Shaw said today.
Biocon Ltd, India top biotechnology company, reported a 4% drop in quarterly profit due to higher energy costs and rise in wages, but said strong demand from branded formulations offered opportunities for growth.
Europe's wealthy have asked to be taxed more, but a top Indian technocrat has put question marks over the ability of the government in India doing a good job with such funds if a law was passed in this regard.
India's largest listed biotechnology firm Biocon's chairperson and managing director Kiran Mazumdar-Shaw is one of India's most successful entrepreneurs.
Expressing concerns over the bureaucratic bottlenecks involved in conducting clinical research and trials in biotechnology sector in India, the industry experts today appealed to the regulatory authorities to stick to the "rule book" rather than "subjectivity".
Speaking to CNBC-TV18 in an exclusive chat, Kiran Mazumdar-Shaw, CMD of Biocon said they are looking to list the research and manufacturing arm of the company, Syngene, in 18 months time.
With the nation's focus on corruption as highlighted by Anna Hazare, business leaders see an opportunity for cleaning up the system by openness and abolition of red tape which generates corruption.
A steep fall in licensing income saw Biocon's net profit fall unexpectedly. Despite an 11% surge in net income, the company's net profit slipped 9% to Rs 70 crore.
Biotechnology company Biocon's consolidated net profit for the first quarter fell almost 9% from a year ago to Rs 70.05 crore, while net sales were up over 10% to Rs 441.68 crore.
Bio-tech queen Kiran Mazumdar-Shaw spills the beans on CNBC-TV18’s Forbes India Show about her past, present and future.
This quarter Biocon's net profit has risen 25% from the same period last year to 101 crore rupees, meeting analyst estimates and to keep this growth going, Biocon is shedding the fat, reports CNBC-TV18's Vineetha Athrey.
The trade and industry council chaired by the Prime Minister met in the capital today. The 23 member council discussed key economic policy issues. CNBC-TV18's Aakansha Sethi reports on the key takeaways from that meeting.
Biocon has had a spectacular third quarter. Its consolidated revenues for the period have surged 15%, and this has helped net profit jump 25%. CNBC-TV18's Vineetha Athrey finds out what Biocon's doing right, and what lies ahead.
The firm is looking at partnerships with global pharma majors as a ticket to hasten the launch of its biotech products